Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 14/20 | 0.73 |
| ▸ | CCND1 | P24385 | 11/20 | 0.73 |
| ▸ | CCND2 | P30279 | 9/20 | 0.73 |
| ▸ | CCND3 | P30281 | 9/20 | 0.73 |
| ▸ | AURKA | O14965 | 2/20 | 0.66 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.62 |
| ▸ | CDK2 | P24941 | 6/20 | 0.62 |
| ▸ | CCNE2 | O96020 | 5/20 | 0.62 |
| ▸ | CSF1R | P07333 | 2/20 | 0.60 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.53 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.53 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.53 |
| ▸ | PAK4 | O96013 | 1/20 | 0.52 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.52 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3968596 | 0.86 | CDK4 (0.83) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL5264096 | 0.84 | CDK4 (1.00) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL12639242 | 0.84 | CDK2 (0.83) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL12305095 | 0.80 | CDK4 (0.75) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL12639089 | 0.80 | CDK4 (0.75) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL3968472 | 0.78 | CDK4 (0.64) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL5517501 | 0.77 | CDK2 (1.00) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL6812292 | 0.77 | CDK4 (0.74) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL4767054 | 0.76 | CSF1R (0.87) | CDK4CCND1CCND2CCND3AURKA | |
| SCHEMBL23804664 | 0.76 | CDK4 (0.81) | CDK4CCND1CCND2CCND3AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947695-B2 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-7947695-B2 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| US-20080070914-A1 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | JANSSEN-CILAG (FR) | 2008-03-20 | — | — | US | disclosed |
| US-20080070914-A1 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | JANSSEN-CILAG (FR) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070914-A1 | Inhibitors of cell cycle kinases such as cyclin dependent kinase CDK4 and/or the Aurora kinases; use in combination with an anticancer agent | CDK1, CDK2, CDK4 | CDK4 3/4885CCND1 34/4885CCND2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.